Organogenesis Holdings Inc. Reports Preliminary Financial Results for Fourth Quarter and Fiscal Year 2020
Last organogenesis holdings inc. - class a earnings: 3/9 04:05 pm
Check Earnings Report
CANTON, Mass., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported preliminary financial results for the three months and twelve months ended December 31, 2020. Fourth Quarter 2020 Preliminary Financial Results Summary: Net revenue of between $104.6 million and $106.0 million for the three months ended December 31, 2020, up 40% to 42% compared to net revenue of $74.6 million for the three months ended December 31, 2019. Net revenue is based upon:? Net revenue from Advanced Wound Care products of between $92.0 million and $93.2 million, up 45% to 47% year-over-year.? Net revenue from Surgical & Sports Medicine products of between $12.6 million and $12.8 million, up 12% to 14% year-over-year.Net revenue from the sale of PuraPly products of between
[Read more]
| Impact snapshot | Event time: | ORGO | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last price | ||
| VWAP | ||
|
High:
|
Max up |
High:
|
|
Low:
|
Max down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event Day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance Since Event
Time and Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
SIGN UP TODAY
Opt-in for
ORGO alerts
ORGO alerts
from News Quantified
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ORGO alerts
High impacting Organogenesis Holdings Inc. - Class A news events
Weekly update
A roundup of the hottest topics
ORGO
News
- Organogenesis Holdings Inc. (<a href="https://www.marketbeat.com/stocks/NASDAQ/ORGO/price-target/">NASDAQ: ORGO</a>) had its "buy" rating re-affirmed by analysts at BTIG Research. They now have a $14.00 price target on the stock, up prevMarketBeat
- Organogenesis Enrolls First Patient in Pivotal Phase 3 Clinical Trial of RMAT-Designated ReNu® for Knee OsteoarthritisGlobeNewswire
- Organogenesis ReNu® Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation For Osteoarthritis of the KneeGlobeNewswire
- Organogenesis Holdings Inc. (<a href="https://www.marketbeat.com/stocks/NASDAQ/ORGO/price-target/">NASDAQ: ORGO</a>) was upgraded by analysts at BidaskClub from a "buy" rating to a "strong-buy" rating.MarketBeat
- Organogenesis Holdings Inc. to Participate in the ICR Conference 2021GlobeNewswire
- More
ORGO
SEC Filings
- 1/13/21 - Form 8-K
- 12/18/20 - Form 8-K
- 12/10/20 - Form 8-K
- ORGO's page on the SEC website
- More